research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-26. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
== See also == List of antidepressants Noradrenergic and specific serotonergic antidepressant (NaSSA) Serotonin releasing agent (SRA) Serotonin–norepinephrine reuptake inhibitor (SNRI) Serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
== January 26, 1982 (Tuesday) == Prime Minister Mauno Koivisto was elected President of Finland by the 301-member Electoral College, receiving 167 votes. He was sworn in the next day to succeed longtime president Urho Kekkonen. Koivistor had obtained 43% of the popular vote in voting on January 17 and January 18 The government of Israel's Prime Minister Menachem Begin survived a vote of no confidecnce by a margin of 55 to 52 regarding compensation to be paid to Israeli citizens who had settled in the Sinai Peninsula, scheduled to be returned to Egypt after 15 years. U.S. President Ronald Reagan delivered his first State of the Union speech since taking office and proposed "New Federalism", the transfer of administration and control of funding for social programs from the U.S. Department of Health and Human Services to the individual state governments. In India, the popular Tamil language film Vaazhvey Maayam (Life is an Illusion), directed by R. Krishnamoorthy, opened at theaters and would run for almost seven months. The romantic drama starred Kamal Haasan, Sridevi and Sripriya. The "Palace on Wheels", a luxury tourist train operated by Indian Railways and the Rajasthan Tourism Development Corporation, began operations. Born: Mamta Kharab, Indian field hockey player and captain of the women's national team; in Givana, Sonipat district, Haryana state Died: Jean Outland Chrysler, 60, American philanthropist and art collector whose donation of works formed the Chrysler Museum of Art; in Norfolk, Virginia
== Childhood obesity == Childhood obesity and adolescent obesity have also increased in Brazil. National surveys and international reports have identified Brazil as one of the countries experiencing a rapid rise in obesity among children and adolescents. Public health experts have expressed concern that increasing childhood obesity may contribute to future increases in diabetes, cardiovascular disease, and healthcare expenditures. The World Obesity Federation has highlighted childhood obesity as an emerging public health challenge in Brazil and throughout Latin America.
==== Hypothalamic-pituitary-thyroid axis downregulation ==== Thyrotropin releasing hormone (TRH) neurons in the hypothalamus integrate global signals about the body's energy state. They may be stimulated by signals such as leptin, alpha-MSH, and catecholamines; and inhibited by glucocorticoids, neuropeptide Y, and agouti-related peptide.
Sources: en.wikipedia.org
In 1927, a Southland Ice Company employee named John Jefferson Green began selling ice, eggs, milk, and bread from 16 ice house storefronts in Dallas, with permission from one of Southland's founding directors, Joe C. Thompson Sr. Although small grocery stores and general merchandisers were available, Thompson theorized that selling products like bread and milk in convenience stores would reduce the need for customers to travel long distances for basic items. Thompson eventually bought the Southland Ice Company and turned it into the Southland Corporation, which oversaw several locations in the Dallas area. In 1928, a manager named Jenna Lira brought a totem pole from Alaska and placed it in front of her store. The pole served as a marketing tool for the company, as it attracted a great deal of attention. Soon, executives added totem poles in front of every store and eventually adopted an Alaska Native-inspired theme. Later on, the stores began operating under the name "Tote'm Stores". That same year, the company began constructing filling stations at some of its Dallas locations as an experiment. Joe Thompson introduced staff training to ensure that customers would receive the same quality and service in every store. Additionally, Southland introduced a uniform for its ice station service boys. In 1931, the Great Depression affected the company, sending it toward bankruptcy. Nevertheless, the company continued its operations through re-organization and receivership. A Dallas banker, W. W.
Specimens may also be stored using nested protective packaging systems; one example is the "Swedish method", in which paper envelopes are placed in cardboard boxes and then in larger rigid boxes. The Muséum national d'histoire naturelle has described varied packaging approaches in its collections, including boxes, envelopes, bound herbarium boards, and specialised slide collections for microscopic groups. The general aim of curation is to preserve both the physical structure needed for morphological study and the chemical integrity required for molecular analysis. Drying techniques vary: heat drying at 40–50 °C (104–122 °F) typically favours the retention of microscopic structures, while freeze-drying preserves colour and macroscopic form at the cost of increased fragility. For damp or woody material, low-temperature drying with high ventilation helps prevent further fungal growth and may limit DNA damage. Although liquid preservation in alcohol or formalin maintains a specimen's three-dimensional shape, it often results in colour loss and DNA degradation. While liquid preservation in glass containers maintains a specimen's three-dimensional shape, the choice of preservation method involves trade-offs between physical integrity and the suitability of the material for future DNA analysis. Because many fungi change markedly in appearance during drying, collecting practice has long included recording features of the living fungus through notes and images; the research value of a specimen is increased when such derivative documentation remains linked to the specimen record.
=== Classes of AID systems === Currently available AID systems fall into three broad classes based on their capabilities. The first systems released can only halt insulin delivery (predictive low glucose suspend) in response to already low or predicted low glucose. Hybrid Closed Loop systems can modulate delivery both up and down, although users still initiate insulin doses (boluses) for meals and typically "announce" or enter meal information. Fully Closed Loops require no manual insulin delivery actions or announcement for meals.
Sources: en.wikipedia.org
=== Ubiquitin-independent degradation === Although most substrates must be ubiquitinated before being degraded by the 26S proteasome, there are some exceptions to this general rule, especially when the proteasome plays a normal role in the post-translational processing of the protein. The proteasomal activation of NF-κB by processing p105 into p50 via internal proteolysis is one major example. Some proteins that are hypothesized to be unstable due to intrinsically unstructured regions, are degraded in a ubiquitin-independent manner. Ubiquitin-independent mechanisms targeting key cell cycle regulators such as p53 have also been reported, although p53 is also subject to ubiquitin-dependent degradation. Finally, structurally abnormal, misfolded, or highly oxidized proteins are also subject to ubiquitin-independent and 19S-independent degradation under conditions of cellular stress. The most well-known example of a ubiquitin-independent proteasome substrate is the enzyme ornithine decarboxylase (ODC). ODC is degraded upon the expression and binding to a cofactor, Ornithine decarboxylase antizyme (AZ) that breaks the ODC dimer. ODC contains either a C-terminal disordered region (in human) or an N-terminal disordered region (in yeast) is necessary for degradation and is proposed to engage the AAA motor of the 19S RP, however the mechanistic details of this interaction have yet to be identified. Another example of ubiquitin independent degradation is Thymidine synthetase, where an N-terminal disordered region is essential for degradation.
== Applying, wearing and using == Injection ports are usually applied by the patient. The device comes with a needle surrounded by a soft cannula. The needle and cannula are manually inserted into the patient's tissue. Immediately after insertion the needle is removed and the cannula remains below the surface of the skin. Ports are usually worn on the abdomen, but can also be worn on other areas such as the buttocks, thigh or arm. Typical injection ports are worn for 3 days and then replaced with another port. Insulin is injected via a syringe into the injection port. Medication immediately flows through the device's cannula into the subcutaneous tissue layer. No medication is stored in the device (other than the small amount of dead-space in the medication channel within the device).
== History == The disease was described in 1933 by Henrik Sjögren, after whom it is named, but several earlier descriptions of people with the symptoms exist. Jan Mikulicz-Radecki (1850–1905) is generally credited with the first description of Sjögren’s. In 1892, he described a 42-year-old man with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. However, the criteria that Mikulicz established for diagnosis often led to misdiagnosis of Mikulicz's syndrome. Many conditions, such as tuberculosis, infections, sarcoidosis, and lymphoma, present with similar conditions to those ascribed to Mikulicz's syndrome. Nevertheless, the term "Mikulicz's syndrome" is still used occasionally to describe the appearance of lymphocytic infiltrates on salivary-gland biopsies. In 1930, Henrik Sjögren (1899–1986), an ophthalmologist in Jönköping, Sweden, observed a patient with low secretions from the lacrimal and salivary glands. Sjögren introduced the term keratoconjunctivitis sicca for the symptom of dry eyes (keratoconjunctivitis). In 1933, he published his doctoral thesis describing 19 females, most of whom were postmenopausal and had arthritis, showing clinical and pathological manifestations of the syndrome. Sjögren clarified that keratoconjunctivitis sicca, resulting from water deficiency, had no relation to xerophthalmia, resulting from vitamin A deficiency. Sjögren's thesis was not well received as the Board of Examiners criticized some clinical aspects.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.